Travere Therapeutics price target raised to $24 from $20 at TD Cowen

TD Cowen analyst Tyler Van Buren raised the firm’s price target on Travere Therapeutics (TVTX) to $24 from $20 and keeps a Buy rating on the shares. The firm updated its model as a preview to Q4 results to reflect the company s pre-reported Q4 Filspari revenue of $50M. They also increased 2025 Filspari estimate to $210M to account for continued steady new patient growth.